Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

169

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions

Hyperphosphatemia

Interventions

DRUG

KHK7791

oral administration

DRUG

Placebo

oral administration

Trial Locations (1)

Inoue Hospital, Suita

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04766398 - Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Biotech Hunter | Biotech Hunter